Biologic response modifier therapy for psoriatic ocular inflammatory disease

Ocular Immunology and Inflammation

Volumn 16, Issue 3, 2008, Pages 89-93

  Huynh, Nancy ^a,b   Cervantes Castaneda, Rene A ^a   Bhat, Pooja ^a   Gallagher, Michael J ^a   Foster, C Stephen ^a,b,c  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

Adalimumab; Infliximab; Ocular inflammation; Psoriasis; Tumor necrosis factor alpha inhibitors

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ADULT; AGED; ARTICLE; BASAL METABOLIC RATE; CLINICAL ARTICLE; CONTROLLED STUDY; EYE INFLAMMATION; FEMALE; HUMAN; MALE; SCLERITIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; REMISSION INDUCTION; SCLERITIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 45749154816     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940802023786     Document Type: Article

References (18)

1. Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis. 1976;35:354.
2. Knox DL. Psoriasis and intraocular inflammation. Trans Am Ophthalmol Soc. 1979;127:270.
3. Sfikakis PP, Theodossiadis PG, Katsiari CG et al. Effect of infliximab on sight threatening panuveitis in Bechets disease. Lancet. 2001;358:295-296.
4. Sfikakis PP, Kaklamanis PH, Elezoglou A et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Bechet disease. Ann Intern Med. 2004;140:404-406.
5. Smith JA, Thompson DJ, Whitcup SM et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18-23.
6. Ali Y, Perlman E. Successful treatment of sarcoidosis. Ann Intern Med. 2004;140:W70.
7. Veale DJ, Ritchlin C, Fitzgerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64:26-29.
8. Forrester JV. Uveitis: pathogenesis. Lancet. 1991;338:1498-1501.
9. De Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res. 1992;11:581-597.
10. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005;52:1227-1236.
11. Antoni C, Kruger GG, de Viam K et al. Infliximab improves the signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-1157.
12. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000;356:385-390.
13. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272.
14. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-3289.
15. Harper SL, Chorich LJ, Foster CS. Diagnosis of uveitis. In: Vitale A, Foster CS, eds. Diagnosis and Treatment of Uveitis. Philadelphia: WB Sanders; 2002;79-97.
16. Lindstedt EW, Baarsma GS, Kuijpers RW et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89:533-536.
17. Suhler EB, Smith JR, Wertheim MS et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903-912.
18. Murphy CC, Ayliffe WH, Booth A et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.